T. Rowe Price Investment Management’s Syndax Pharmaceuticals SNDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-85,511
| Closed | -$1.65M | – | 670 |
|
|
2024
Q3 | $1.65M | Sell |
85,511
-198,316
| -70% | -$3.82M | ﹤0.01% | 591 |
|
|
2024
Q2 | $5.83M | Sell |
283,827
-2,175,408
| -88% | -$44.7M | ﹤0.01% | 565 |
|
|
2024
Q1 | $58.5M | Sell |
2,459,235
-252,018
| -9% | -$6M | 0.04% | 365 |
|
|
2023
Q4 | $58.6M | Buy |
2,711,253
+1,644,705
| +154% | +$35.5M | 0.04% | 369 |
|
|
2023
Q3 | $15.5M | Hold |
1,066,548
| – | – | 0.01% | 500 |
|
|
2023
Q2 | $22.3M | Buy |
1,066,548
+65,833
| +7% | +$1.38M | 0.02% | 464 |
|
|
2023
Q1 | $21.1M | Sell |
1,000,715
-2,171
| -0.2% | -$45.9K | 0.02% | 465 |
|
|
2022
Q4 | $25.5M | Buy |
1,002,886
+79,660
| +9% | +$2.03M | 0.02% | 435 |
|
|
2022
Q3 | $22.2M | Buy |
+923,226
| New | +$22.2M | 0.02% | 440 |
|